Better Health, Brighter FutureNews Release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF
THE RELEVANT LAWS OF SUCH JURISDICTION
Takeda Announces Cancellation of Remaining Commitments under the Bridge Credit Agreement inConnection with the Proposed Acquisition of Shire plc- Takeda successfully completed take-out financing as planned December 21, 2018 (London time) --- Takeda Pharmaceutical Company Limited (TSE:4502) (the“Company or “Takeda”) announces that it intends to fund the cash consideration due on completion of theproposed acquisition of Shire plc (the “Acquisition”) from its cash resources and other financing sources,and earlier today, December 21, 2018 (London time), cancelled in full the remaining commitments under the364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (asamended on June 8, 2018 and October 26, 2018) (the “Bridge Credit Agreement”).
In addition, certain technical amendments are being made to the Term Loan Credit Agreement dated June 8,2018 (the “Term Loan”), the Senior Short-Term Loan Facility Agreement dated October 26, 2018 (the“SSTL”) and the Loan Agreement with the Japan Bank for International Cooperation dated December 3,2018 (the “JBIC Loan”) entered into by Takeda (such amendments being made by way of amendment
agreements to the Term Loan, the SSTL and the JBIC Loan respectively (the “Amendment Agreements”)).
In accordance with Rule 26 of the City Code on Takeovers and Mergers, copies of the Amendment
Agreements will be published on Takeda's website and will be available to view at
www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day
following the date of this announcement or, if later, the date on which the relevant Amendment Agreement issigned.

Media and Investor Contacts:
Takeda (Investor Relations)Takashi Okubo
takeda.ir.contact@takeda.com+81 3 3278 2306
1

Takeda (Media – inside Japan)
Kazumi Kobayashi
kazumi.kobayashi@takeda.com+81 3 3278 2095
Takeda (Media – outside Japan)
Elissa Johnsen
Elissa.Johnsen@takeda.com+1 312 285 3203
Tsuyoshi Tada
Tsuyoshi.Tada@takeda.com+1 617 551 2933About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven
pharmaceutical company committed to bringing better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology andneuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stayat the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well
as Takeda's presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000
Takeda employees are committed to improving quality of life for patients, working with Takeda's partners inhealth care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.
Important NoticeThis announcement is not intended to, and does not, constitute, represent or form part of any offer, invitation
or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, anysecurities whether pursuant to this announcement or otherwise.
The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may berestricted by law or regulation and therefore any person who comes into possession of this announcement
should inform themselves about, and comply with, such restrictions. Any failure to comply with such
restrictions may constitute a violation of the securities laws or regulations of any such relevant jurisdiction.
Publication on Website
In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject tocertain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at
www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day
following the date of this announcement. The content of the website referred to in this announcement is notincorporated into and does not form part of this announcement.
Disclosure requirements of the Code2

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities
of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in
respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an
Opening Position Disclosure following the commencement of the offer period and, if later, following theannouncement in which any securities exchange offeror is first identified. An Opening Position Disclosuremust contain details of the person's interests and short positions in, and rights to subscribe for, any relevant
securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position
Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time)on the 10th business day following the commencement of the offer period and, if appropriate, by no later
than 3.30 pm (London time) on the 10th business day following the announcement in which any securities
exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offereecompany or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosuremust instead make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class ofrelevant securities of the offeree company or of any securities exchange offeror must make a Dealing
Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchangeofferor. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests andshort positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and(ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed
under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than
3.30 pm (London time) on the business day following the date of the relevant dealing.
If two or more persons act together pursuant to an agreement or understanding, whether formal or informal,
to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror,
they will be deemed to be a single person for the purpose of Rule 8.3.
Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing
Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert
with any of them (see Rules 8.1, 8.2 and 8.4).
Details of the offeree and offeror companies in respect of whose relevant securities Opening Position
Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's
website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when
the offer period commenced and when any offeror was first identified. You should contact the Panel's Market
Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an
Opening Position Disclosure or a Dealing Disclosure.

###3